Copyright
©The Author(s) 2015.
World J Gastrointest Oncol. Dec 15, 2015; 7(12): 401-410
Published online Dec 15, 2015. doi: 10.4251/wjgo.v7.i12.401
Published online Dec 15, 2015. doi: 10.4251/wjgo.v7.i12.401
Figure 1 Molecular targets and relevant drugs in metastatic gastric cancer.
HER: Human epidermal growth factor receptor; VEGF: Vascular endothelial growth factor; VEGFR: Vascular endothelial growth factor receptor; PDGFR: Platelet-derived growth factor receptor; HGF: Hepatocyte growth factor; FGFR2: Fibroblast growth factor receptor 2; IGF-1: Insulin-like growth factor 1; Raf: GTPase Raf; Ras: GTPase Ras; MEK: MAP kinase; ERK: Extracellular-signal-regulated kinase; PI3K: Phosphatidylinositol 3-kinase; PTEN: Phosphatase and tensin homolog; AKT: Protein kinase B; mTOR: Mammalian target of rapamycin.
Figure 2 Proposed targeted therapy algorithm for advanced gastric cancer.
CF: Cisplatin plus 5-Fluorouracil; HER: Human epidermal growth factor receptor; CX: Cisplatin plus capecitabine.
- Citation: Kanat O, O’Neil B, Shahda S. Targeted therapy for advanced gastric cancer: A review of current status and future prospects. World J Gastrointest Oncol 2015; 7(12): 401-410
- URL: https://www.wjgnet.com/1948-5204/full/v7/i12/401.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v7.i12.401